Annotation Detail for GRIK1
Basic Information
Top
Pathway ID | Pathway Name |
---|
hsa04080 | Neuroactive ligand-receptor interaction |
Pathway ID | Pathway Name |
---|
| Synaptic Transmission |
Pathway ID | Pathway Name |
---|
P00039 | Metabotropic glutamate receptor group III pathway |
P00037 | Ionotropic glutamate receptor pathway |
P00029 | Huntington disease |
P00041 | Metabotropic glutamate receptor group I pathway |
Desease Name |
---|
Huntington Disease |
CANCER |
epilepsy |
PSYCH |
breast cancer |
NEUROLOGICAL |
hyperactive-impulsive symptoms |
Desease Name |
---|
Hyperactive-impulsive symptoms |
Response to statin therapy |
Breast cancer |
Chemical ID |
Chemical Name |
Interaction |
Interaction Action |
Publication |
---|
C084273 |
5-nitro-6,7,8,9-tetrahydrobenzo(G)indole-2,3-dione-3-oxime |
5-nitro-6,7,8,9-tetrahydrobenzo(G)indole-2,3-dione-3-oxime binds to and results in decreased activity of GRIK1 protein | affects binding|decreases activity | 19596362
|
D000643 |
Ammonium Chloride |
Ammonium Chloride affects the expression of GRIK1 mRNA | affects expression | 16483693
|
D020185 |
Benzoic Acids |
Benzoic Acids analog binds to and results in decreased activity of GRIK1 protein | affects binding|decreases activity | 14667236
|
D005038 |
Ethylnitrosourea |
Ethylnitrosourea results in increased mutagenesis of GRIK1 gene | increases mutagenesis | 16495775
|
C025299 |
polyphenols |
polyphenols results in decreased expression of GRIK1 mRNA | decreases expression | 16293270
|
C002979 |
selenomethylselenocysteine |
selenomethylselenocysteine results in increased expression of GRIK1 mRNA | increases expression | 18514395
|
D018038 |
Sodium Selenite |
Sodium Selenite results in increased expression of GRIK1 mRNA | increases expression | 18514395
|
C052342 |
topiramate |
GRIK1 gene SNP affects the susceptibility to topiramate | affects response to substance | 19331489
|
Disease ID |
Disease Name |
Direct Evidence |
Inference Chemical Name |
Inference Score |
Publication |
---|
MESH:D000138 |
Acidosis |
|
Ammonium Chloride |
3.90 | 18287403 |
MESH:D000236 |
Adenoma |
|
Ethylnitrosourea |
3.84 | 6695378 |
MESH:D000437 |
Alcoholism |
|
topiramate |
5.21 | 17925516 19331489 18552399 |
MESH:D001927 |
Brain Diseases |
|
Ethylnitrosourea |
5.11 | 14991843 |
MESH:D001932 |
Brain Neoplasms |
|
Ethylnitrosourea |
4.52 | 16357521 15144691 18412241 16436596 16651633 |
MESH:D001943 |
Breast Neoplasms |
|
selenomethylselenocysteine |
3.77 | 18855134 |
MESH:D002471 |
Cell Transformation, Neoplastic |
|
Ethylnitrosourea |
3.88 | 16003739 |
MESH:D016543 |
Central Nervous System Neoplasms |
|
Ethylnitrosourea |
6.36 | 17160924 |
MESH:D002659 |
Child Development Disorders, Pervasive |
|
topiramate |
4.17 | 15650499 |
MESH:D019457 |
Chromosome Breakage |
|
Sodium Selenite |
5.06 | 15894690 |
MESH:D003110 |
Colonic Neoplasms |
|
polyphenols |
2.70 | 16293270 |
MESH:D003920 |
Diabetes Mellitus |
|
Sodium Selenite |
3.99 | 16285004 |
MESH:D003924 |
Diabetes Mellitus, Type 2 |
|
topiramate |
3.74 | 16979414 |
MESH:D056486 |
Drug-Induced Liver Injury |
|
polyphenols |
4.45 | 19370779 |
MESH:D056486 |
Drug-Induced Liver Injury |
|
Sodium Selenite |
4.45 | 15131321 |
MESH:D004476 |
Ectodermal Dysplasia |
|
Ethylnitrosourea |
6.36 | 18357618 |
MESH:D004827 |
Epilepsy |
|
topiramate |
4.43 | 19148780 |
MESH:D004833 |
Epilepsy, Temporal Lobe |
|
topiramate |
6.65 | 16499746 |
MESH:D005909 |
Glioblastoma |
|
Ethylnitrosourea |
3.98 | 16436596 |
MESH:D005910 |
Glioma |
|
Ethylnitrosourea |
3.57 | 16651633 16357521 18412241 |
MESH:D007249 |
Inflammation |
|
polyphenols |
3.17 | 16366677 |
MESH:D007333 |
Insulin Resistance |
|
Sodium Selenite |
3.42 | 14714311 |
MESH:D007680 |
Kidney Neoplasms |
|
Ethylnitrosourea |
4.13 | 17379185 |
MESH:D008107 |
Liver Diseases |
|
polyphenols |
2.83 | 16698588 |
MESH:D008175 |
Lung Neoplasms |
|
Ethylnitrosourea |
2.63 | 17703301 16271038 6695378 16019985 |
MESH:D008223 |
Lymphoma |
|
Ethylnitrosourea |
4.11 | 15790496 |
MESH:D016393 |
Lymphoma, B-Cell |
|
Sodium Selenite |
4.32 | 14737004 |
MESH:D016399 |
Lymphoma, T-Cell |
|
Ethylnitrosourea |
5.35 | 15375218 |
MESH:D008325 |
Mammary Neoplasms, Experimental |
|
Ethylnitrosourea |
7.39 | 10838139 10767621 18041768 |
MESH:D008325 |
Mammary Neoplasms, Experimental |
|
selenomethylselenocysteine |
7.39 | 15318939 |
MESH:D008579 |
Meningioma |
|
Ethylnitrosourea |
6.36 | 17943659 |
MESH:D008881 |
Migraine Disorders |
|
topiramate |
4.74 | 16942474 18803445 18759728 18765137 |
MESH:D009374 |
Neoplasms, Experimental |
|
Ethylnitrosourea |
4.71 | 16707424 |
MESH:D009442 |
Neurilemmoma |
|
Ethylnitrosourea |
5.75 | 16003739 17160924 16651423 |
MESH:D009837 |
Oligodendroglioma |
|
Ethylnitrosourea |
6.36 | 17160924 |
MESH:D011471 |
Prostatic Neoplasms |
|
Sodium Selenite |
3.35 | 18760546 |
MESH:D012640 |
Seizures |
|
topiramate |
4.28 | 16499746 |
MESH:D013705 |
Temporomandibular Joint Disorders |
|
polyphenols |
5.63 | 17997062 |
MESH:D013953 |
Thymus Neoplasms |
|
Ethylnitrosourea |
5.50 | 15790496 |
PharmGKB Accession:PA28973
Releated disease ID |
Related disease Name |
PA443309 | Alcoholism |
Drugbank ID |
Action |
Drug Name |
Description |
---|
DB00142 |
- |
L-Glutamic Acid |
Dietary supplement;Micronutrient;Non-Essential Amino Acids |
DB00273 |
antagonist |
Topiramate |
Anticonvulsants;Anti-Obesity Agents;Neuroprotective Agents |